Elanco and Aratana Therapeutics finalize deal to mergeJuly 18, 2019Elanco Animal Health has acquired Aratana Therapeutics. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. "Aratana's strong position in the specialty market—with its current portfolio and pipeline—complements Elanco's field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands," says Jeff Simmons, president and chief executive officer of Elanco. "This deal furthers Elanco's value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians and pet owners." Aratana produces Galliprant, a canine NSAID for osteoarthritis for which Elanco has had the exclusive rights to develop, manufacture, and commercialize since 2016. Aratana also contributes two additional products to Elanco's portfolio: Entyce, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Further, Aratana's research and development pipeline will contribute to Elanco's efforts to sustain the introduction of novel and innovative companion animal therapeutics. As a result of the acquisition, Elanco says it is forming a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. This specialty sales force will …
SPONSORED CONTENTSee What the ACVIM Recommends for Certain Types of Canine CHFSafe, effective treatment that's approved by the FDA for management of certain types of canine CHF. + Learn More
FDA approves ProHeart 12July 8, 2019The U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM) has approved ProHeart 12 (moxidectin) extended release injectable suspension for dogs one year and older.
Aratana Therapeutics' Nocita 10 ml gets FDA approvalJune 13, 2019Aratana Therapeutics announced the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has approved an additional vial size (10 ml) of Nocita. "Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries," says Aratana Therapeutics chief development officer, Ernst Heinen, DVM, PhD. "Ultimately, we believe a smaller vial size may allow for expanded use and improve the level of care veterinarians provide for certain painful surgeries." Nocita, which is currently available in a 20-ml vial size, is a local postoperative analgesia for cranial cruciate ligament surgery in dogs and a peripheral nerve block following owner-elected onychectomy (declawing) in cats. The smaller vial size is expected to be made commercially available in fall 2019.
ISU to begin canine anticancer immunotherapeutic agent clinical trialsFebruary 28, 2019Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic. Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored. "Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades," said Chad Johannes, DVM, DACVIM (SAIM, oncology). "Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs." Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv and enter AAHSD004874 in the keyword search.
Is there a gold-standard test for adverse food reactions?February 14, 2019Some of the most common conditions seen in small-animal practice are gastrointestinal complaints, such as vomiting and diarrhea, and skin problems, including pruritis.1 Among the many differential diagnoses for these symptoms are adverse food reactions (AFRs).
FDA accepting grant applications for new drugs to treat minor speciesNovember 27, 2018The U.S. Food and Drug Administration (FDA) is accepting applications for grants to support the development of new animal drugs intended to treat uncommon diseases in major or minor species (MUMS).
Responses to the virtual mailbagNovember 16, 2018It has been a little over a year since I took over this column from Dr. Narda Robinson, and I have enjoyed the opportunity to explore many interesting topics through the lens of evidence-based medicine (EBM). One core element of EBM is substantive, critical debate, and discussion about the merits and limitations of published research evidence. Every stakeholder, from clinicians to researchers to those in industry to the owners of veterinary patients, will have a different mix of goals and perspectives. The interplay among different sets of biases is one of the mechanisms for cutting through bias generally and achieving an accurate understanding of nature that informs safer and more effective patient care. One of the strengths of science is that it requires a community process.
Brain Teaser: Can you solve this puzzle?November 1, 2018 Presentation A patient is dysphoric when recovering from anesthesia. Challenge How do you diagnose dysphoria? What do you need to differentiate dysphoria from? How would you treat dysphoria? Check your answer on the next page.
Brain Teaser: Can you solve this puzzle?October 17, 2018 Presentation Cystotomy in a five-year-old Rottweiler who had 178 struvite stones. Challenge What is the holding layer—the one to include in the suture line? Which suture material is ideal? Which needle is best? Which suture pattern is recommended? Check your answer on the next page.
VolitionRx tests nucleosome diagnostic for veterinary space applicationsOctober 5, 2018 VolitionRx Ltd., a multinational Belgium-based life sciences company with offices in Texas, London, and Singapore, announced it is entering the veterinary market after "very encouraging" preliminary results from a study using its NuQ diagnostic blood tests for canine cancer testing. NuQ, currently used to screen for colorectal and prostate cancers, works by measuring and analyzing irregular levels of nucleosomes—a section of DNA wrapped around a core of proteins—in the blood to identify cancers. According to the company, the proof-of-concept study showed that blood nucleosomes also can be detected in dogs. With the promise of veterinary medicine applications, VolitionRx said it will now move NuQ into larger trials to answer the question of whether the method will work with animals. The company said it intends to outsource much of the veterinary clinical trial work through a partnership with Heather Wilson-Robles, DVM, DACVIM, associate professor and Fred and Vola N. Palmer chair in comparative oncology with Texas A&M College of Veterinary Medicine & Biomedical Sciences in the Small Animal Clinical Sciences department. "The Texas A&M University College of Veterinary Medicine Oncology Department is excited for the opportunity to collaborate with Volition," said Dr. Wilson-Robles. "Its innovative work in …
